Pharmafile Logo

How pharma companies can use AI to scale personalized engagement without increasing complexity

November 3, 2026 | AI, Pharma, healthcare 

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing a new tool – it requires high levels of data, system maturity, and a new approach to the way assets are produced.

- PMLiVE

Insights from Inizio experts Kristin Ryan, Lauren Turner, and Christen Jones. 

Why AI is changing pharma customer engagement 

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing a new tool – it requires high levels of data, system maturity, and a new approach to the way assets are produced.  

The past 30 years have witnessed several waves of digital disruption. First, we had the web, which made information virtual and more widespread, followed by search engines that made it more easily discoverable. We then had social, which made information shareable, and mobile, which made it responsive and accessible anywhere. We’re now well into the latest stage of disruption: AI, which is making information more personalized than ever.  

“While AI may seem daunting, we’ve been through technological disruption before and we’ve made it work – and now we’re making AI work as well,” explains Kristin Ryan, EVP of AI Transformation & Acceleration at Inizio Evoke.   

“Each new capability feels novel and perhaps a little scary at first, but then it quickly becomes something that people just expect in their digital experiences. And that’s really important for our sector because audiences aren’t comparing healthcare experiences with healthcare experiences. Their expectations are shaped by the best digital interactions they’re having in all areas of their life, whether that’s the adaptive recommendations of Netflix or the predictive convenience of Amazon.” 

The difference is, if Netflix gets it wrong and recommends a show you don’t like, it doesn’t matter too much. But in healthcare, the wrong answer can have serious consequences. So, the drive isn’t just for personalization, but personalization that also brings flawless accuracy, compliance, and good governance. Patients want answers that really understand who they are, where they are on their health journey, what they’re trying to decide, and what their next steps should be. 

Read the full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

How pharma companies can use AI to scale personalized engagement without increasing complexity

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing…

Creating the conditions for product launch success in a time of volatility

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

Navigating uncertainty in life sciences

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments….

Inizio appoints Oisín Ó Gógáin as Chief People Officer

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

Pharma leadership strategies for talent, AI adoption, and continuous learning

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous…

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Intelligent Commercialization™ across the pharma lifecycle

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

Four steps to a smarter congress strategy: A practical guidebook

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…